Sudarshan Pharma [SUDARSHAN] vs Gujarat Alkalies [GUJALKALI] Detailed Stock Comparison
Sudarshan Pharma
BSE
Loading...
Gujarat Alkalies
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Sudarshan Pharma wins in 7 metrics, Gujarat Alkalies wins in 11 metrics, with 0 ties. Gujarat Alkalies appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Sudarshan Pharma | Gujarat Alkalies | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 29.86 | 70.12 | Sudarshan Pharma |
| Price-to-Book Ratio | 4.76 | 0.68 | Gujarat Alkalies |
| Debt-to-Equity Ratio | 129.85 | 9.30 | Gujarat Alkalies |
| PEG Ratio | N/A | -1.02 | N/A |
| EV/EBITDA | 16.49 | 11.23 | Gujarat Alkalies |
| Profit Margin (TTM) | 3.83% | -0.82% | Sudarshan Pharma |
| Operating Margin (TTM) | 6.99% | 1.34% | Sudarshan Pharma |
| EBITDA Margin (TTM) | 6.99% | 1.34% | Sudarshan Pharma |
| Return on Equity | 12.13% | -1.15% | Sudarshan Pharma |
| Return on Assets (TTM) | 3.96% | -0.82% | Sudarshan Pharma |
| Free Cash Flow (TTM) | $304.76M | $557.34M | Gujarat Alkalies |
| Dividend Yield | N/A | 4.82% | N/A |
| 1-Year Return | -93.27% | -35.85% | Gujarat Alkalies |
| Price-to-Sales Ratio (TTM) | 1.13 | 0.97 | Gujarat Alkalies |
| Enterprise Value | $7.94B | $45.24B | Gujarat Alkalies |
| EV/Revenue Ratio | 1.44 | 1.08 | Gujarat Alkalies |
| Gross Profit Margin (TTM) | 11.05% | 60.26% | Gujarat Alkalies |
| Revenue per Share (TTM) | $23 | $573 | Gujarat Alkalies |
| Earnings per Share (Diluted) | $0.87 | $-4.72 | Sudarshan Pharma |
| Beta (Stock Volatility) | 0.68 | -0.38 | Gujarat Alkalies |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Sudarshan Pharma vs Gujarat Alkalies Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Sudarshan Pharma | 4.99% | 4.88% | -15.13% | -6.93% | -11.29% | -38.71% |
| Gujarat Alkalies | -1.04% | 3.23% | -5.46% | -2.36% | -6.65% | -24.87% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Sudarshan Pharma | -93.27% | -51.13% | -51.13% | -51.13% | -51.13% | -51.13% |
| Gujarat Alkalies | -35.85% | -36.55% | 78.76% | 234.03% | 329.61% | 296.96% |
News Based Sentiment: Sudarshan Pharma vs Gujarat Alkalies
Sudarshan Pharma
News based Sentiment: NEGATIVE
Sudarshan Pharma faces significant headwinds, including a substantial year-to-date stock decline, negative analyst ratings predicting a 48% decline, and concerning valuation metrics. While the upcoming IPO presents a potential opportunity, the overall narrative is one of caution and risk, making this a pivotal moment for the company.
Gujarat Alkalies
News based Sentiment: MIXED
The month featured a significant earnings turnaround for Gujarat Alkalies, but this was coupled with conflicting analyst signals and recent stock performance declines. While the Q1 results are positive, the mixed sentiment creates uncertainty for investors, making this a moderately important month for the company's investment story.
Performance & Financial Health Analysis: Sudarshan Pharma vs Gujarat Alkalies
| Metric | SUDARSHAN | GUJALKALI |
|---|---|---|
| Market Information | ||
| Market Cap | ₹6.56B | ₹41.82B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 53,200 | 37,677 |
| 90 Day Avg. Volume | 77,333 | 50,754 |
| Last Close | ₹28.63 | ₹555.65 |
| 52 Week Range | ₹24.69 - ₹53.50 | ₹483.60 - ₹900.00 |
| % from 52W High | -46.49% | -38.26% |
| All-Time High | ₹452.70 (Sep 30, 2024) | ₹1,044.70 (May 02, 2022) |
| % from All-Time High | -93.68% | -46.81% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.46% | 0.13% |
| Quarterly Earnings Growth | N/A | 0.13% |
| Financial Health | ||
| Profit Margin (TTM) | 0.04% | -0.01% |
| Operating Margin (TTM) | 0.07% | 0.01% |
| Return on Equity (TTM) | 0.12% | -0.01% |
| Debt to Equity (MRQ) | 129.85 | 9.30 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹5.46 | ₹819.92 |
| Cash per Share (MRQ) | ₹0.09 | ₹20.86 |
| Operating Cash Flow (TTM) | ₹8.46M | ₹-2,688,119,000 |
| Levered Free Cash Flow (TTM) | ₹159.55M | ₹-651,186,000 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 4.82% |
| Last 12-Month Dividend | N/A | ₹29.65 |
Valuation & Enterprise Metrics Analysis: Sudarshan Pharma vs Gujarat Alkalies
| Metric | SUDARSHAN | GUJALKALI |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 29.86 | 70.12 |
| Forward P/E | N/A | 6.43 |
| PEG Ratio | N/A | -1.02 |
| Price to Sales (TTM) | 1.13 | 0.97 |
| Price to Book (MRQ) | 4.76 | 0.68 |
| Market Capitalization | ||
| Market Capitalization | ₹6.56B | ₹41.82B |
| Enterprise Value | ₹7.94B | ₹45.24B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.44 | 1.08 |
| Enterprise to EBITDA | 16.49 | 11.23 |
| Risk & Other Metrics | ||
| Beta | 0.68 | -0.38 |
| Book Value per Share (MRQ) | ₹5.46 | ₹819.92 |
Financial Statements Comparison: Sudarshan Pharma vs Gujarat Alkalies
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | SUDARSHAN | GUJALKALI |
|---|---|---|
| Revenue/Sales | ₹1.45B | ₹11.05B |
| Cost of Goods Sold | ₹1.29B | ₹4.39B |
| Gross Profit | ₹160.46M | ₹6.66B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹101.60M | ₹147.50M |
| EBITDA | ₹122.50M | ₹1.04B |
| Pre-Tax Income | ₹54.09M | ₹-120.20M |
| Income Tax | ₹14.51M | ₹17.60M |
| Net Income (Profit) | ₹39.59M | ₹-137.80M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | SUDARSHAN | GUJALKALI |
|---|---|---|
| Cash & Equivalents | ₹5.51M | ₹1.26B |
| Total Current Assets | ₹3.35B | ₹10.55B |
| Total Current Liabilities | ₹2.60B | ₹9.33B |
| Long-Term Debt | ₹104.60M | ₹5.35B |
| Total Shareholders Equity | ₹1.31B | ₹56.70B |
| Retained Earnings | N/A | ₹16.56B |
| Property, Plant & Equipment | ₹200.50M | ₹2.20B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | SUDARSHAN | GUJALKALI |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | SUDARSHAN | GUJALKALI |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 53,200 | 37,677 |
| Average Daily Volume (90 Day) | 77,333 | 50,754 |
| Shares Outstanding | 240.66M | 73.44M |
| Float Shares | 71.19M | 17.12M |
| % Held by Insiders | 0.76% | 0.78% |
| % Held by Institutions | 0.00% | 0.04% |
Dividend Analysis & Yield Comparison: Sudarshan Pharma vs Gujarat Alkalies
| Metric | SUDARSHAN | GUJALKALI |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹29.65 |
| Last 12-Month Dividend Yield | N/A | 4.82% |
| 3-Year Avg Annual Dividend | N/A | ₹21.07 |
| 3-Year Avg Dividend Yield | N/A | 2.19% |
| 3-Year Total Dividends | N/A | ₹63.20 |
| Ex-Dividend Date | N/A | Sep 19, 2025 |